Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MYGN | US
0.01
0.04%
Healthcare
Diagnostics & Research
30/06/2024
30/08/2024
28.33
28.36
28.97
27.84
Myriad Genetics Inc. a genetic testing and precision medicine company develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test a DNA sequencing test to help determine the therapy for patients with metastatic breast ovarian metastatic pancreatic or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition the company offers Prolaris Prostate Cancer Prognostic Test a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor a solution for precision oncology; and Prequel Prenatal Screen a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further it provides Foresight Carrier Screen a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression anxiety ADHD and other mental health conditions. Myriad Genetics Inc. has a strategic collaboration with Illumina Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City Utah.
View LessPositive Momentum
Strength based on increasing price with high volume
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
21.5%1 month
28.3%3 months
29.8%6 months
45.6%-
312.50
3.47
-
-
-23.47
3.26
1.40
-49.00M
2.57B
2.57B
-
-11.77
-
15.30
-21.03
4.49
5.98
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.82
Range1M
4.16
Range3M
7.86
Rel. volume
1.28
Price X volume
25.03M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twist Bioscience Corporation | TWST | Diagnostics & Research | 43.24 | 2.53B | -3.70% | n/a | 17.75% |
NeoGenomics Inc | NEO | Diagnostics & Research | 16.52 | 2.12B | 0.61% | n/a | 66.22% |
Soleno Therapeutics Inc | SLNO | Diagnostics & Research | 48.95 | 1.90B | 5.12% | n/a | 0.11% |
CareDx Inc | CDNA | Diagnostics & Research | 30.73 | 1.62B | -0.58% | n/a | 11.88% |
CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 29.67 | 822.95M | -0.40% | n/a | 5.94% |
Fulgent Genetics Inc | FLGT | Diagnostics & Research | 22.56 | 683.49M | -2.42% | n/a | 1.18% |
Celcuity Inc | CELC | Diagnostics & Research | 15.96 | 590.98M | -0.93% | n/a | 54.62% |
Surmodics Inc | SRDX | Diagnostics & Research | 39.63 | 565.40M | -0.10% | n/a | 28.32% |
National Research Corporation | NRC | Diagnostics & Research | 22.8 | 544.27M | 2.33% | 19.16 | 105.03% |
Varex Imaging Corporation | VREX | Diagnostics & Research | 12.48 | 509.95M | 1.63% | 16.86 | 80.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 22.73 | 2.83B | 2.11% | 87.42 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.85 | 2.54B | 1.32% | 21.80 | 76.47% |
AMC Entertainment Holdings Inc | AMC | Media - Diversified | 4.82 | 1.74B | 0.00% | n/a | -511.14% |
Lions Gate Entertainment Corp | LGF-B | Media - Diversified | 6.92 | 1.74B | 0.44% | n/a | 28882.88% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 59.66 | 1.73B | 0.15% | 22.26 | 56.33% |
Lions Gate Entertainment Corp | LGF-A | Media - Diversified | 7.77 | 1.72B | -0.26% | n/a | 28882.88% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.48 | 1.69B | -0.47% | 41.31 | 64.69% |
REV Group Inc | REVG | Recreational Vehicles | 31.84 | 1.65B | 1.69% | 7.49 | 66.74% |
Steelcase Inc | SCS | Building Products & Equipment | 14.14 | 1.61B | 1.87% | 18.36 | 69.98% |
Janus International Group Inc. | JBI | Building Products & Equipment | 10.99 | 1.60B | 0.92% | 12.35 | 116.21% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -23.47 | 12.26 | Cheaper |
Ent. to Revenue | 3.26 | 41.25 | Cheaper |
PE Ratio | - | 39.64 | - |
Price to Book | 3.47 | 74.32 | Cheaper |
Dividend Yield | - | 1.12 | - |
Std. Deviation (3M) | 29.82 | 63.86 | Lower Risk |
Debt to Equity | - | 0.32 | - |
Debt to Assets | - | 0.34 | - |
Market Cap | 2.57B | 13.31B | Emerging |